Skip Navigation

Irene Ghobrial, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Michele & Steven Kirsch Laboratory
  • Director, Clinical Investigator Research Program
  • Senior Physician
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Multiple myeloma
  • Waldenström’s Macroglobulinemia

Contact Information

  • Appointments617-632-3823 (new)
    617-632-4218 (follow-up)
  • Office Phone Number617-632-4218
  • Fax617-582-8608

Bio

Dr. Ghobrial received her MD in 1995 from Cairo University School of Medicine, Egypt. She completed her Internal Medicine training at Wayne State University, Mich., and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, Minn.

She joined Dana-Farber in the field of Waldenstrom's macroglobulinemia and multiple myeloma in 2005. She is conducting research in the area of homing and migration of B cells and novel therapeutic agents in Waldenstrom's macroglbulinemia and multiple myeloma.

Board Certification:

  • Hematology, 2004
  • Internal Medicine, 2001
  • Medical Oncology, 2004

Fellowship:

  • Mayo Clinic, Graduate Medical Education, Hematology & Oncology

Residency:

  • Cairo University School of Medicine, Pediatrics
  • Sinai-Grace Hospital of Detroit, Internal Medicine

Medical School:

  • Cairo University School of Medicine

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Harvard Institute of Medicine 240
Boston MA, 02215
Get Directions

Research

Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018 Jan 09.
View in: PubMed

Sula Karreci E, Eskandari SK, Dotiwala F, Routray SK, Kurdi AT, Assaker JP, Luckyanchykov P, Mihali AB, Maarouf O, Borges TJ, Alkhudhayri A, Patel KR, Radwan A, Ghobrial I, McGrath M, Chandraker A, Riella LV, Elyaman W, Abdi R, Lieberman J, Azzi J. Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight. 2017 Nov 02; 2(21).
View in: PubMed

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, Rosen CJ, Reagan MR. Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. Endocrinology. 2017 10 01; 158(10):3369-3385.
View in: PubMed

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM. Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. Curr Osteoporos Rep. 2017 Oct; 15(5):499-506.
View in: PubMed

Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM. A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. Am J Hematol. 2017 Aug; 92(8):E138-E145.
View in: PubMed

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
View in: PubMed

Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, Roccaro AM. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget. 2017 May 23; 8(21):35435-35444.
View in: PubMed

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017 06 29; 129(26):3452-3464.
View in: PubMed

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA, Ghobrial IM. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017 May 10; 9(389).
View in: PubMed

Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
View in: PubMed

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 Apr 04; 19(1):218-224.
View in: PubMed

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 2017 Nov; 31(11):2426-2434.
View in: PubMed

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92(5):448-453.
View in: PubMed

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2017 03 01; 28(3):468-477.
View in: PubMed

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 04 27; 129(17):2429-2436.
View in: PubMed

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
View in: PubMed

Kawano Y, Roccaro AM, Ghobrial IM, Azzi J. Multiple Myeloma and the Immune Microenvironment. Curr Cancer Drug Targets. 2017; 17(9):806-818.
View in: PubMed

Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM. Established and Novel Prognostic Biomarkers in Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2017; 37:548-560.
View in: PubMed

Sula Karreci E, Fan H, Uehara M, Mihali AB, Singh PK, Kurdi AT, Solhjou Z, Riella LV, Ghobrial I, Laragione T, Routray S, Assaker JP, Wang R, Sukenick G, Shi L, Barrat FJ, Nathan CF, Lin G, Azzi J. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 Dec 27; 113(52):E8425-E8432.
View in: PubMed

Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
View in: PubMed

Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, Daley GQ, Ghobrial IM. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017 Apr; 31(4):853-860.
View in: PubMed

Sacco A, Fenotti A, Bazzana S, Imberti L, Rossi G, Patterson CJ, Treon SP, Ghobrial IM, Roccaro AM. Epigenomics in Waldenstrom's macroglobulinaemia. Best Pract Res Clin Haematol. 2016 Jun; 29(2):156-160.
View in: PubMed

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017 02; 14(2):100-113.
View in: PubMed

Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr Opin Hematol. 2016 Jul; 23(4):426-33.
View in: PubMed

Rotenstein L, Nathan A, Ghobrial I, Antin J, Parnes A. Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 11; 51(11):1504-1506.
View in: PubMed

Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5.
View in: PubMed

Abbott RD, Wang RY, Reagan MR, Chen Y, Borowsky FE, Zieba A, Marra KG, Rubin JP, Ghobrial IM, Kaplan DL. The Use of Silk as a Scaffold for Mature, Sustainable Unilocular Adipose 3D Tissue Engineered Systems. Adv Healthc Mater. 2016 Jul; 5(13):1667-77.
View in: PubMed

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F. Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
View in: PubMed

Castillo JJ, Ghobrial IM, Treon SP. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 Nov; 57(11):2699-701.
View in: PubMed

Roccaro AM, Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
View in: PubMed

Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia. 2016 05; 30(5):1103-15.
View in: PubMed

Sacco A, Roccaro AM, Ma D, Shi J, Mishima Y, Moschetta M, Chiarini M, Munshi N, Handin RI, Ghobrial IM. Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Res. 2016 Jan 15; 76(2):463-71.
View in: PubMed

Manier S, Salem KZ, Liu D, Ghobrial IM. Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. Am Soc Clin Oncol Educ Book. 2016; 35:e400-6.
View in: PubMed

Glavey SV, Manier S, Sacco A, Salem K, Kawano Y, Bouyssou J, Ghobrial IM, Roccaro AM. Epigenetics in Multiple Myeloma. Cancer Treat Res. 2016; 169:35-49.
View in: PubMed

Manier S, Salem K, Glavey SV, Roccaro AM, Ghobrial IM. Genomic Aberrations in Multiple Myeloma. Cancer Treat Res. 2016; 169:23-34.
View in: PubMed

Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S, Roccaro AM. Exosomes in Tumor Angiogenesis. Methods Mol Biol. 2016; 1464:25-34.
View in: PubMed

Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
View in: PubMed

Bouyssou JM, Ghobrial IM, Roccaro AM. Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett. 2016 09 28; 380(1):315-8.
View in: PubMed

Dimopoulos MA, Kastritis E, Ghobrial IM. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics. Ann Oncol. 2016 Feb; 27(2):233-40.
View in: PubMed

Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A, Costello R, Zhang Y, Kurlander RJ, Korde N, Roccaro AM, Ghobrial IM, Landgren O, Calvo KR. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. J Mol Diagn. 2015 Nov; 17(6):669-78.
View in: PubMed

Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH. Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist. 2015 Sep; 20(9):1077-83.
View in: PubMed

Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, Glavey S, Morgan E, Pan C, Michor F, Cardarelli P, Kuhne M, Ghobrial IM. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015 Jul 28; 12(4):622-35.
View in: PubMed

Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46.
View in: PubMed

Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
View in: PubMed

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Line A, Lipps G, Llorente A, Lötvall J, Mancek-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4:27066.
View in: PubMed

Leblebjian H, Noonan K, Paba-Prada C, Treon SP, Castillo JJ, Ghobrial IM. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
View in: PubMed

Salem KZ, Ghobrial IM. The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs. 2015 Apr 12; 3(6).
View in: PubMed

Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
View in: PubMed

Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
View in: PubMed

Glavey SV, Ghobrial IM. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Expert Rev Hematol. 2015 Jun; 8(3):273-5.
View in: PubMed

Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC, Ghobrial IM. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015 May 15; 75(10):2071-82.
View in: PubMed

Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone. 2015 Jun; 75:161-9.
View in: PubMed

Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, Roccaro AM, Ghobrial IM, Joshi L, O'Dwyer ME. The cancer glycome: carbohydrates as mediators of metastasis. Blood Rev. 2015 Jul; 29(4):269-79.
View in: PubMed

Castillo JJ, Ghobrial IM, Treon SP. Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
View in: PubMed

Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015 Jan; 263(1):160-72.
View in: PubMed

Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
View in: PubMed

Zhang W, Wang YE, Zhang Y, Leleu X, Reagan M, Zhang Y, Mishima Y, Glavey S, Manier S, Sacco A, Jiang B, Roccaro AM, Ghobrial IM. Global epigenetic regulation of microRNAs in multiple myeloma. PLoS One. 2014; 9(10):e110973.
View in: PubMed

Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. Blood. 2014 Nov 27; 124(23):3380-8.
View in: PubMed

Bianchi G, Ghobrial IM. Team work matters: dual inhibition puts non-hodgkin lymphoma under siege. Clin Cancer Res. 2014 Dec 01; 20(23):5863-5.
View in: PubMed

Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 2014 Oct 09; 9(1):118-28.
View in: PubMed

Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia. Mol Cancer Res. 2015 Feb; 13(2):263-72.
View in: PubMed

Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, Roccaro AM, Ghobrial IM. Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86.
View in: PubMed

Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, Roccaro AM, Ghobrial IM. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood. 2014 Nov 20; 124(22):3250-9.
View in: PubMed

Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, Roccaro AM, Azab AK, Ghobrial IM. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Am J Hematol. 2014 Nov; 89(11):1030-6.
View in: PubMed

Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, Roccaro AM, Ghobrial IM, O'Dwyer ME. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 2014 Sep 11; 124(11):1765-76.
View in: PubMed

Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O. Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine. 2014 Oct; 69(2):294-7.
View in: PubMed

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
View in: PubMed

Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014 Jul 15; 111(28):10287-92.
View in: PubMed

Zabora J, Buzaglo J, Kennedy V, Richards T, Schapmire T, Zebrack B, Ghobrial IM. Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma. Palliat Support Care. 2015 Aug; 13(4):829-38.
View in: PubMed

Patel CG, Yee AJ, Scullen TA, Nemani N, Santo L, Richardson PG, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Raje NS. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
View in: PubMed

Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
View in: PubMed

Sahin I, Moschetta M, Mishima Y, Glavey SV, Tsang B, Azab F, Manier S, Zhang Y, Maiso P, Sacco A, Azab AK, Roccaro AM, Ghobrial IM. Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer J. 2014 Apr 25; 4:e204.
View in: PubMed

Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
View in: PubMed

Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, Aljawai Y, Sahin I, Kuhne M, Cardarelli P, Cohen L, San Miguel JF, Garcia-Sanz R, Ghobrial IM. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014 Jun 26; 123(26):4120-31.
View in: PubMed

Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, Roccaro AM, Ghobrial IM. Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta. 2014 Aug; 1846(1):26-39.
View in: PubMed

Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O'Driscoll L. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014 Mar 24; 13:71.
View in: PubMed

Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, DeAngelo D, Treon SP. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar; 89(3):237-42.
View in: PubMed

Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014 Apr; 1845(2):255-65.
View in: PubMed

Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
View in: PubMed

Sahin I, Leblebjian H, Treon SP, Ghobrial IM. Waldenström macroglobulinemia: from biology to treatment. Expert Rev Hematol. 2014 Feb; 7(1):157-68.
View in: PubMed

Glavey S, Manier S, Sacco A, Rossi G, Ghobrial IM, Roccaro AM. The role of miRNAs in plasma cell dyscrasias. Microrna. 2014; 2(3):165-73.
View in: PubMed

Bianchi G, Ghobrial IM. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Curr Cancer Ther Rev. 2014; 10(2):70-79.
View in: PubMed

Roccaro AM, Ghobrial IM. microRNA aberrations and their role in supporting hematologic malignancies. Microrna. 2014; 2(3):157.
View in: PubMed

Leblebjian H, Agarwal A, Ghobrial I. Novel treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S310-6.
View in: PubMed

Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet. 2013; 6:33-42.
View in: PubMed

Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS One. 2013; 8(6):e66982.
View in: PubMed

Ghobrial IM. Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new? Leuk Lymphoma. 2013 Oct; 54(10):2328-30.
View in: PubMed

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65.
View in: PubMed

Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013 Apr; 123(4):1542-55.
View in: PubMed

Ghobrial IM. Update on Waldenström's macroglobulinemia. Clin Adv Hematol Oncol. 2013 Apr; 11(4):244-6.
View in: PubMed

Agarwal A, Ghobrial IM. The bone marrow microenvironment in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):218-21.
View in: PubMed

Sacco A, Zhang Y, Maiso P, Manier S, Rossi G, Treon SP, Ghobrial IM, Roccaro AM. microRNA aberrations in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):205-7.
View in: PubMed

Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
View in: PubMed

Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013 Jun; 54(6):1135-41.
View in: PubMed

Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
View in: PubMed

Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
View in: PubMed

Ghobrial IM. Choice of therapy for patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2013 Jan 20; 31(3):291-3.
View in: PubMed

Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013 Mar 01; 19(5):985-94.
View in: PubMed

Azab AK, Weisberg E, Sahin I, Liu F, Awwad R, Azab F, Liu Q, Griffin JD, Ghobrial IM. The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia. 2013 Apr; 27(4):961-4.
View in: PubMed

Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
View in: PubMed

Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Clin Cancer Res. 2012 Dec 15; 18(24):6609-22.
View in: PubMed

Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012; 2012:157496.
View in: PubMed

Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL. Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer. 2012 Sep; 15(3):273-82.
View in: PubMed

Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013 Feb; 54(2):229-41.
View in: PubMed

Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Leblond V. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res. 2012 Sep 15; 18(18):5043-50.
View in: PubMed

Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86.
View in: PubMed

Maiso P, Ghobrial IM. Would the real myeloma cell please stand up? Leuk Lymphoma. 2012 Oct; 53(10):1851-2.
View in: PubMed

Howard S, Jagannathan J, Krajewski K, Giardino A, Zukotynski K, O'Regan K, Ghobrial I, Ramaiya N. Multimodality imaging in amyloidosis. Cancer Imaging. 2012 Apr 27; 12:109-17.
View in: PubMed

Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012 Jul 05; 120(1):20-30.
View in: PubMed

Bianchi G, Ghobrial IM. Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am. 2012 Apr; 26(2):383-93, ix.
View in: PubMed

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
View in: PubMed

Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94.
View in: PubMed

Bianchi G, Kumar S, Ghobrial IM, Roccaro AM. Cell Trafficking in Multiple Myeloma. Open J Hematol. 2012 Feb 21; 3(Suppl 1).
View in: PubMed

Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
View in: PubMed

Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program. 2012; 2012:586-94.
View in: PubMed

Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012 May; 26(5):985-90.
View in: PubMed

Issa NC, Koo S, Lynch RC, Gay C, Hammond SP, Baden LR, Ghobrial IM, Finkelman MA, Marty FM. Serum galactomannan and (1->3)-ß-D-glucan assays for patients with multiple myeloma and Waldenstrom's macroglobulinemia. J Clin Microbiol. 2012 Mar; 50(3):1054-6.
View in: PubMed

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
View in: PubMed

Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 09; 119(6):1468-78.
View in: PubMed

Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2012 Jan 15; 18(2):342-9.
View in: PubMed

Sacco A, Ghobrial IM, Roccaro AM. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia. Curr Cancer Drug Targets. 2011 Nov; 11(9):1025-9.
View in: PubMed

Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22; 118(26):6860-70.
View in: PubMed

Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, Roccaro AM, Sacco A, Ngo HT, Zhang Y, Morgan BL, Carrasco RD, Ghobrial IM. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res. 2012 Jan 01; 18(1):91-104.
View in: PubMed

Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
View in: PubMed

Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
View in: PubMed

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
View in: PubMed

Ghobrial IM, Maiso P, Azab A, Liu Y, Zhang Y, Issa G, Azab F, Sacco A, Quang P, Ngo H, Roccaro A. The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol. 2011 Aug; 2(4):267-72.
View in: PubMed

Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, Chauhan D, Ghobrial IM, Munshi N, Anderson KC. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
View in: PubMed

Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011 Jul; 86(7):567-72.
View in: PubMed

Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol. 2011 Jul; 18(4):260-5.
View in: PubMed

Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
View in: PubMed

Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
View in: PubMed

Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa GC, Leleu X, Roccaro AM. Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S65-9.
View in: PubMed

Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 2011 Jul 01; 17(13):4389-99.
View in: PubMed

Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NJ. Integrin ß7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011 Jun 09; 117(23):6202-13.
View in: PubMed

Leleu X, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N, Weller E, Ghobrial IM. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Clin Cancer Res. 2011 May 01; 17(9):3013-8.
View in: PubMed

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84.
View in: PubMed

Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res. 2011 Apr 01; 17(7):1753-64.
View in: PubMed

Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
View in: PubMed

Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):109-11.
View in: PubMed

Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM. Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):164-7.
View in: PubMed

Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, Roccaro A. The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):118-20.
View in: PubMed

Calvo KR, Landgren O, Roccaro AM, Ghobrial IM. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin Hematol. 2011 Jan; 48(1):39-45.
View in: PubMed

Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011 Jan-Feb; 16(1):011006.
View in: PubMed

Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenström macroglobulinemia. Clin Investig (Lond). 2011; 1(6):815-824.
View in: PubMed

Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7.
View in: PubMed

Roper N, DeAngelo DJ, Kuo F, Dal Cin P, Ghobrial I, Aster JC. An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol. 2010 Dec; 85(12):944-6.
View in: PubMed

Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. 2010 Nov; 1(7):578-82.
View in: PubMed

Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, Roccaro AM. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol. 2010 Oct 07; 3:38.
View in: PubMed

Sacco A, Ghobrial IM, Roccaro AM. Epigenetics in Waldenström's macroglobulinemia. Epigenomics. 2010 Oct; 2(5):691-6.
View in: PubMed

Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010 Oct; 51(10):1779-92.
View in: PubMed

Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
View in: PubMed

Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
View in: PubMed

Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010 Sep 02; 116(9):1506-14.
View in: PubMed

Sacco A, Leleu X, Rossi G, Ghobrial IM, Roccaro AM. Novel agents in Waldenstrom Macroglobulinemia. Open J Hematol. 2010 May 28; 1.
View in: PubMed

Richardson P, Laubach J, Mahindra A, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Raje N, Munshi N, Anderson K. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
View in: PubMed

Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
View in: PubMed

Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
View in: PubMed

Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
View in: PubMed

Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
View in: PubMed

Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
View in: PubMed

Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010 May 20; 115(20):4051-60.
View in: PubMed

Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 01; 16(3):1033-41.
View in: PubMed

Stedman J, Roccaro A, Leleu X, Ghobrial IM. New Therapeutic Approaches for Waldenstrom Macroglobulinemia. Drugs Future. 2010 Jan; 35(1):53-58.
View in: PubMed

Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010 Jan 21; 115(3):559-69.
View in: PubMed

Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
View in: PubMed

Stedman J, Roccaro A, Ghobrial IM. Individualizing treatment for Waldenstrom's macroglobulinemia. Expert Rev Hematol. 2009 Oct; 2(5):473-6.
View in: PubMed

Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
View in: PubMed

Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res. 2009 Oct 01; 15(19):6035-41.
View in: PubMed

Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
View in: PubMed

Laubach JP, Mitsiades CS, Hideshima T, Schlossman R, Chauhan D, Munshi N, Ghobrial I, Carreau N, Anderson KC, Richardson PG. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
View in: PubMed

Venon MD, Roccaro AM, Gay J, Moreau AS, Dulery R, Facon T, Ghobrial IM, Leleu X. Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics. 2009; 3:99-109.
View in: PubMed

Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10; 27(23):3830-5.
View in: PubMed

Roccaro AM, Sacco A, Leleu X, Thompson B, Azab A, Runnels J, Lin C, Witzig T, Anderson K, Ghobrial I. MicroRNAs 15a and 16-1 regulates tumor proliferation in multiple myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):e14640.
View in: PubMed

Anderson KC, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M, Ghobrial I, Knight R, Esseltine D, Richardson P. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):8536.
View in: PubMed

Ghobrial IM, Matous J, Padmanabhan S, Badros A, Chuma S, Leduc R, Rourke M, Kunsman J, Harris B, Warren D, Richardson P. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):8535.
View in: PubMed

Azab A, Azab F, Runnels J, Roccaro AM, Magnani JL, Sarkar A, Anderson KC, Lin CP, Ghobrial IM. Role of selectins in the pathogenesis of multiple myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):11103.
View in: PubMed

Harris B, Leleu X, Leduc R, Yarar D, Sam A, Rourke M, Chuma S, Roccaro A, Ghobrial I. Diagnostic and prognostic use of FDG-PET scans in Waldenstrom's macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):e19518.
View in: PubMed

Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16; 114(3):619-29.
View in: PubMed

Laubach JP, Mitsiades CS, Roccaro AM, Ghobrial IM, Anderson KC, Richardson PG. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
View in: PubMed

Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25; 113(26):6669-80.
View in: PubMed

Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69(8):3579-88.
View in: PubMed

Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Bortezomib and Waldenstrom's macroglobulinemia. Expert Opin Pharmacother. 2009 Apr; 10(5):909-16.
View in: PubMed

Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Lévy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, Treon SP, Leblond V. Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3.
View in: PubMed

Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009 Mar; 9(1):39-42.
View in: PubMed

Roccaro AM, Sacco A, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem M, Moreau AS, Ghobrial IM. Role of proteasome inhibition in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):94-6.
View in: PubMed

Ghobrial IM, Leleu X, Azab AK, Runnels J, Jia X, Ngo H, Melhem M, Azab F, Sacco A, Quang P, Burwick N, Moreau AS, Husu E, Farag M, Roccaro A. Novel therapeutic agents in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):84-6.
View in: PubMed

Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63.
View in: PubMed

Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
View in: PubMed

Gertz MA, Ghobrial I, Luc-Harousseau J. Multiple myeloma: biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):46-52.
View in: PubMed

Ghobrial IM, Laubach JP, Soiffer RJ. Finding the right academic job. Hematology Am Soc Hematol Educ Program. 2009; 729-33.
View in: PubMed

Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM. Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol. 2009 Jan; 82(1):1-12.
View in: PubMed

Ghobrial IM, Stewart AK. ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology Am Soc Hematol Educ Program. 2009; 587-9.
View in: PubMed

Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402.
View in: PubMed

Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5.
View in: PubMed

Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 Jan 01; 27(1):120-6.
View in: PubMed

Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34.
View in: PubMed

Roccaro AM, Ghobrial IM, Blotta S, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
View in: PubMed

Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, Foon K, Ghobrial IM. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008 Sep; 49(9):1738-44.
View in: PubMed

Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC. The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
View in: PubMed

Ansell SM, Inwards DJ, Rowland KM, Flynn PJ, Morton RF, Moore DF, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008 Aug 01; 113(3):508-14.
View in: PubMed

Alsayed Y, Leleu X, Leontovich A, Oton AB, Melhem M, George D, Ghobrial IM. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur J Haematol. 2008 Oct; 81(4):298-303.
View in: PubMed

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
View in: PubMed

Leleu X, Roccaro AM, Moreau AS, Dupire S, Robu D, Gay J, Hatjiharissi E, Burwik N, Ghobrial IM. Waldenstrom macroglobulinemia. Cancer Lett. 2008 Oct 18; 270(1):95-107.
View in: PubMed

Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85.
View in: PubMed

Burwick N, Roccaro AM, Leleu X, Ghobrial IM. Targeted therapies in Waldenström macroglobulinemia. Curr Opin Investig Drugs. 2008 Jun; 9(6):631-7.
View in: PubMed

Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008 Jun; 49(6):1104-7.
View in: PubMed

Richardson PG, Lonial S, Jakubowiak A, Jagannath S, Raje N, Avigan D, Ghobrial IM, Knight R, Esseltine D, Anderson KC. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol. 2008 May 20; 26(15_suppl):8520.
View in: PubMed

Ghobrial IM, Leleu X, Rubin N, Leduc R, Chuma S, Nelson M, Sportelli P, Richardson PG, Treon SP, Anderson KC. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2008 May 20; 26(15_suppl):8546.
View in: PubMed

Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008 Jul 01; 112(1):150-8.
View in: PubMed

Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
View in: PubMed

Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
View in: PubMed

Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Le Friec G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol. 2008 Jun; 80(6):503-9.
View in: PubMed

Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63.
View in: PubMed

Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
View in: PubMed

Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
View in: PubMed

Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
View in: PubMed

Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 01; 13(13):3771-5.
View in: PubMed

Ghobrial IM, Ghobrial J, Leleu X, Hatjiharissi E, Mitsiades C, Richardson P, . Novel Therapeutic Avenues in Myeloma: Changing the Paradigm. Oncology. 2007.
View in: PubMed

Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
View in: PubMed

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
View in: PubMed

Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84.
View in: PubMed

Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007 Apr 01; 109(7):2708-17.
View in: PubMed

Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
View in: PubMed

Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 01; 109(11):4964-72.
View in: PubMed

Burwick N, Leleu X, Ghobrial IM, Mitsiades C, Richardson P. Novel treatments in multiple myeloma. Hospital Pharmacy Europe. 2007; 81-83.
View in: PubMed

O'Sullivan, Leleu X, Moreau AS, Jia X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The combination of the mTOR inhibitor rapamycin and proteasome inhibitor Bortezomib is synergistic in vitro in Multiple Myeloma. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Ghobrial IM, Foon, K. Non-Hodgkin Lymphoma. William's Hematology. 2007.
View in: PubMed

Younes H, Leleu X, Hatjiharissi E, Moreau AS, Anderson KC, Ghobrial IM. Targeting the PI3K pathway in Multiple Myeloma. Clinical Cancer Research. 2007.
View in: PubMed

Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
View in: PubMed

Leleu X, Jia X, Moreau AS, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Perifosine, an oral bioactive AKT inhibitor induces in vitro and in vivo antitumor activity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Runnels J, Pitsillides C, Spenser J, Ngo N, Hatjiharissi E, Leleu X, Moreau AS, Jia X, Hideshima T, Anderson KC, Ghobrial IM. A novel real-time in vivo homing model of multiple myeloma. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Huston A, Leleu X, Jia X, Moreau A, Ngo H, Runnels J, Anderson J, Alsayed Y, Richardson P, Hideshima T, Roodman D, Anderson KC, Ghobrial IM. Targeting Akt and HSP90 produces synergistic Multiple Myeloma cell cytoxicity in the bone marrow microenvironment. Blood. 2007.
View in: PubMed

Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The Proteasome inhibitor NPI-0052 incombination with bortezomib induces antitumor activity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Moreau AS, Jia X, O'Sullivan, Leleu X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. A selective protein kinase C inhibitor Enzastaurin, induces in vitro and in vivo cytotoxicity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Ngo N, Hatjiharissi E, Leleu X, Runnels J, Moreau AS, Jia X, O'Sullivan, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The PI3k/Akt pathway is an important regulator of homing and adhesion in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
View in: PubMed

Ghobrial IM, Dimopoulos A. Update on novel therapeutic agents in Waldenstom Macroglobulinemia. Translational Therapeutic Strategies in Multiple Myeloma. 2007.
View in: PubMed

Leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4.
View in: PubMed

Hwang JJ, Ghobrial IM, Anderson KC. New frontiers in the treatment of multiple myeloma. ScientificWorldJournal. 2006 Dec 06; 6:1475-503.
View in: PubMed

Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6826-35.
View in: PubMed

Richardson PG, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
View in: PubMed

Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I, Raje N, Munshi N, Anderson KC. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007 Apr 05; 26(16):2374-80.
View in: PubMed

Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol. 2006 Oct; 34(10):1289-95.
View in: PubMed

Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, Kyle RA, Dispenzieri A, Lacy MQ, Rajkumar SV, Gertz MA, Fonseca R. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006 Sep; 169(2):150-3.
View in: PubMed

Ghobrial IM, Richardson P. The emerging role of novel therpeutic agents int he management of patients with multiple myeloma. Community Oncology. 2006; 3(9):575-582.
View in: PubMed

Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108(8):2755-63.
View in: PubMed

Patterson CJ, Soumerai J, Hunter Z, Leleu X, Ghobrial I, Treon SP. Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7556.
View in: PubMed

Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133(2):158-64.
View in: PubMed

Leleu X, Jia X, Moreau AS, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Perifosine, an oral bioactive AKT inhibitor induces in vitro and in vivo antitumor activity in Waldenstroms Macroglobulinemia. ASH. 2006.
View in: PubMed

Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. ASH. 2006.
View in: PubMed

O'Sullivan, Leleu X, Moreau AS, Jia X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The combination of the mTOR inhibitor rapamycin and proteasome inhibitor Bortezomib in synergistic in vitro in Multiple Myeloma. ASH. 2006.
View in: PubMed

Moreau AS, Jia X, O'Sullivan, Leleu X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. A selection protein kinase C inhibitor Enzastaurin, induces in vitro and in vivo cytotoxicity in Waldenstrom Macroglobulinemia. ASH. 2006.
View in: PubMed

Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC< Ghobrial IM. The Proteasome inhibitor NPI-0052 incombination with bortezomib induces antitumor activity in Waldenstrom Macroglobulinemia. ASH. 2006.
View in: PubMed

Ngo N, Hatjiharissi E, Leleu X, Runnels J, Moreau AS, Jia X, O'Sullivan, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom Macroglobulinemia. ASH. 2006.
View in: PubMed

Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM . The PI3K/Akt pathway is an important regulator of homing and adhesion in Waldenstrom Macroglobulinemia. ASH. 2006.
View in: PubMed

Runnels J, Pitsillides C, Spenser J, NGO N, Hatjiharissi E, Leleu X, Moreau AS, Jia X, Hideshima T, Anderson KC, Ghobrial IM. A novel real-time in vivo homing model of multiple myeloma. ASH. 2006.
View in: PubMed

Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006 Apr 15; 107(8):3098-105.
View in: PubMed

Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005 Oct 20; 23(30):7574-82.
View in: PubMed

Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10; 23(23):5347-56.
View in: PubMed

Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005 Aug 15; 106(4):1407-14.
View in: PubMed

Ghobrial IM, Weenig RH, Pittlekow MR, Qu G, Kurtin PJ, Ristow K, Ansell SM. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005 May; 46(5):703-8.
View in: PubMed

Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 May-Jun; 55(3):178-94.
View in: PubMed

Eckel-Passow JE, Hoering A, Therneau TM, Ghobrial I. Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays. Cancer Res. 2005 Apr 15; 65(8):2985-9.
View in: PubMed

Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, McGregor CG. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005 Feb; 46(2):191-6.
View in: PubMed

Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005 Jan 27; 79(2):244-7.
View in: PubMed

Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 2005 May 01; 105(9):3722-30.
View in: PubMed

Alsayed YM, Leontocich A, Timm M, Melham M, Ghobrial IM. Proteomic analysis of Waldenstrom Macroglobulinemia (WM) using nanoscale protein microarray techniques. ASH. 2005.
View in: PubMed

Huston A, Leontocich A, Timm M, Alsayed YM, Ghobrial IM. Proteomic analysis identifies differences in multiple myeloma (MM) cells sensitive and resistant to AKT inhibition. ASH. 2005.
View in: PubMed

Ghobrial IM, Timm M, Witzig T. Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. 10th Annual Myeloma Workshop. 2005.
View in: PubMed

Lu Y, Keller E, Dai J, Escara-Wilke J, Ghobrial IM, et al. Role of cathepsin K in prostate cancer skeletal meastasis. AACR. 2005.
View in: PubMed

Ghobrial IM, Timm M, Witzig T . Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). 10th International Myeloma Workshop. 2005.
View in: PubMed

Lu Y, Keller E, Dai J, Escara-Wilke J, Ghobrial IM, et al . Role of cathepsin K in prostate cancer skeletal metastasis. AACR. 2005.
View in: PubMed

Alsayed YM, Leontovish A, Timm M, Melhem M, Ghobrial IM. Proteomic analysis of post transplant lymphoproliferative disorders (PTLD) using nanoscale protein microarray techniques. ASH. 2005.
View in: PubMed

Lu Y, Keller E, Yao Z, Taichman R, Ghobrial IM, et al . Zoledronic acid inhibits CXCR-4-mediated prostate cancer cell invasion through an NFɻB independent pathway in vitro. AACR. 2005.
View in: PubMed

Alsayed YM, Singha U, Huston A, Roodman GD, Ghobrial IM. Differential response to proteosome inhibition in EBV positive and negative lymphoma cell lines: clinical implications in post transplant lymphoproliferative disorders (PtLD). 2005.
View in: PubMed

Ghobrial IM, Ghobrial JM, Bramati P, Kumar A, Hedin K, Witzig T. Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of The PI3K Pathway. 10Th International Myeloma Workshop. 2005.
View in: PubMed

Ghobrial IM, Timm M, Witzig T . Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. 10Th International Myeloma Workshop. 2005.
View in: PubMed

Francis L, Anderson J, Timm M, Roodman GD, Ghobrial IM. The effect of rapamycin, 17-AAG and the combination on the bone marrow microenvironment in Multiple Myeloma (MM). ASH. 2005.
View in: PubMed

Ghobrial IM, Alsayed YM, Timm M, et al. Molecular mechanisms regulating migration and adhesion in response to the chemokine SDF-1 in multiple myeloma (MM). ASH. 2005.
View in: PubMed

Huston A, Alsayed YM, Singha U, Francis L, Roodman GD, Ghobrial IM. Combination of the AKT inhibitor perifosine with the HSP90 inhibitor 17-(dimethylaminoethyulamino)-17-demethoxygeldanamycin (17-DMAG) has synergistic activity in Multiple Myeloma (MM). ASH. 2005.
View in: PubMed

Lu Y, Keller E, Yao Z, Taichman R, Ghobrial IM, et al. Zoledronic acid inhibits CXCR-4 mediated prostate cancer cell invasion through an NFE>>B independent pathway in vitro. AACR. 2005.
View in: PubMed

Ghobrial IM, Timm M, Witzig T, Kedin K. The Role of CXCR4 inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. 10th Annyal Internation Myeloma Workshop. 2005.
View in: PubMed

Lanie K, Ganwei L, Ujjal S, Lentsch S, Roodman GD, Ghobrial IM, . Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17AAG in Multiple Myeloma. ASCO. 2005.
View in: PubMed

Huston A, Singha U, Alsayed YM, Roodman GD, Ghobrial IM. The role of the AKT inhibitor perifosine in migration and adhesion in multiple myeloma (MM). ASH. 2005.
View in: PubMed

Ghobrial IM, Sigha U, Alsayed YM, et al. Role of the chemokine receptor CXCR4 in Waldenstrom Macroglobulinemia. ASH. 2005.
View in: PubMed

Alsayed YM, Singha U, Francis L, Roodman GD, Ghobrial IM. Combination of the mTOR inhibitor rapamycin with the HSP90 inhibitor 17-AAG has synergistic activity in EBV positive and negative post transplant lymphoproliferative disorders (PTLD). ASH. 2005.
View in: PubMed

Ghobrial IM, Timm M, Witzig T Hedin K . The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. 10Th International Myeloma Workshop. 2005.
View in: PubMed

Ghobrial IM, Melhem M, Ujjal S, et al. Role of the CXCR4 inhibitor AMD3100 in mulitple myeloma (MM). ASH. 2005.
View in: PubMed

Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol. 2004 Dec; 77(4):329-30.
View in: PubMed

Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 01; 101(11):2593-8.
View in: PubMed

Ghobrial IM, McCormick DJ, Kaufmann SH, Ansell SM, Novak AJ, Stenson MJ, Krajnik KL, Witzig TE. Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6530.
View in: PubMed

Ghobrial IM, Buadi F, Spinner RJ, Colgan JP, Wolanskyj AP, Dyck PJ, Witzig TE, Micallef IN, O'Neill BP. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer. 2004 Jun 01; 100(11):2403-7.
View in: PubMed

Ghobrial IM, Witzig TE. Waldenström macroglobulinemia. Curr Treat Options Oncol. 2004 Jun; 5(3):239-47.
View in: PubMed

Ghobrial I, Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology (Williston Park). 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640.
View in: PubMed

Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc. 2004 Mar; 79(3):318-25.
View in: PubMed

Ghobrial IM, Bunch TJ, Caplice NM, Edwards WD, Miller DV, Litzow MR. Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clin Proc. 2004 Mar; 79(3):403-6.
View in: PubMed

Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75.
View in: PubMed

Ghobrial IM, Timm M, Witzig T . Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). ASH. 2004.
View in: PubMed

Chung T, Kim S, Baker A, Price-Troska T, Xu R, Ghobrial IM, Greipp R, Rajkumar SV, Gertz MA, Van Weir S, Ahmann G, Carpten J, Fonseca R . Characterization of Waldenström Macroglobulinemia Subtypes Using Global Gene Expression Profiling. ASH. 2004.
View in: PubMed

Ghobrial IM, Ghobrial JM, Bramati P, Kumar A, Hedin K, Witzig T . Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway. ASH. 2004.
View in: PubMed

Eckel JE, Hoering A, Ghobrial IM . Experimental Design & Analysis of Protein Array Data: Applying Methods from cDNA Arrays. ASH. 2004.
View in: PubMed

Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM . Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. National Institute of Health. 2004.
View in: PubMed

Ghobrial IM. Kaufman S, Witzig T . CCI-779 inhibits phosphorylation of ribosomal S6 (pS6) in mantle cell lymphoma. AACR. 2004.
View in: PubMed

Ghobrial IM, Timm M, Greipp P, Fonseca R, Witzig T . Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy . ASH. 2004.
View in: PubMed

Ghobrial IM, Ghobrial JM, Bramati P, Kumar A, Hedin K, Witzig T . Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of The PI3K Pathway. ASH. 2004.
View in: PubMed

Ghobrial IM, Timm M, Witzig T, Hedin K . The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. ASH. 2004.
View in: PubMed

Ghobrial IM, McCormick, Witzig, T . Proteomic analysis of mantle cell lymphoma. National Institute of Health. 2004.
View in: PubMed

Ghobrial IM, Timm M, Greipp P, Witzig T. Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy. ASH. 2004.
View in: PubMed

Ghobrial IM, McCormick D, Witzig T . Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90 and other proteins as potential target(s) for drug therapy. ASCO. 2004.
View in: PubMed

Riter HG, Ghobrial IM. Renal cell carcinoma with acrometastasis and scalp metastasis. Mayo Clin Proc. 2004 Jan; 79(1):76.
View in: PubMed

Witzig TE, Geyer S, Ghobrial IM, et al . Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. ASH . 2004.
View in: PubMed

Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med. 2003 Dec 25; 349(26):2570-2; discussion 2570-2.
View in: PubMed

Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol. 2003 Nov; 4(11):679-85.
View in: PubMed

Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV, Therneau TM, Lacy MQ, Witzig TE, Litzow MR, Christensen BR, Hayman S, Pribula CG, Gertz MA. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant. 2003 Sep; 32(6):587-92.
View in: PubMed

Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003 Sep-Oct; 1(3):194-205.
View in: PubMed

Ghobrial IM, Habermann TM, Geyer S, Ansell S. Rituximab and IPI are prognostic indicators in post transplant lymphoproliferative disorders (PTLD). American Society of Clinical Oncology. 2003.
View in: PubMed

Ghobrial IM, Habermann T . Differences between early and late Post Transplant Lymphoproliferative Disorders: are they two different diseases. Blood. 2003.
View in: PubMed

Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Panpacific Lymphoma Conference. 2003.
View in: PubMed

Ghobrial IM, ONeill B . CNS Post Transplant Lymphoproliferative Disorders: therapy with rituximab. Blood. 2003.
View in: PubMed

Ghobrial IM, Fonseca R, Gertz M, Greipp P, Kyle R. . The IgM flare in patients diagnosed with Waldenstrom Macroglobulinemia and treated with rituximab: an ECOG study. Blood. 2003.
View in: PubMed

Gthobrial IM, Fonseca R, Gertz M, Greipp P, Kyle R. Prognostic model for 506 patients diagnosed with Waldenstrom Macroglobulinemia,. Blood. 2003.
View in: PubMed

Ghobrial IM, Ansell AM . Subcutaneous Panniculitis-like T cell lymphoma: clinical presentation and follow up of 17 patients. Blood. 2003.
View in: PubMed

Xu R, Van Wier S, Ghobrial IM, Schop R, Ahmann G, Greipp P, Kyle R, Rajkumar SV, Gertz MA, Fonseca R . Deletions of 6q predominantly involve band q23 and distinguish Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Blood. 2003.
View in: PubMed

Ghobrial IM, Habermann T . Prognostic model for patients with Post Transplant Lymphoproliferative Disorders. Blood. 2003.
View in: PubMed

Ghobrial IM, Wolf R, Fonseca R, Witzig T. . Therapeutic options in patients with lymphoma and severe liver dysfunction. Blood. 2003.
View in: PubMed

Ghobrial IM, Adjei AA. Inhibitors of the ras oncogene as therapeutic targets. Hematol Oncol Clin North Am. 2002 Oct; 16(5):1065-88.
View in: PubMed

Woodle ES, Thistlethwaite JR, Jolliffe LK, Ghobrial I, Fuccello AJ, Stuart FP, Bluestone JA. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc. 1991 Feb; 23(1 Pt 1):81-2.
View in: PubMed

Wong JT, Eylath AA, Ghobrial I, Colvin RB. The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation. 1990 Oct; 50(4):683-9.
View in: PubMed

Raskova J, Ghobrial I, Shea SM, Ebert EC, Eisinger RP, Raska K. T cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity, and interleukin-2 production and receptor generation. Diagn Immunol. 1986; 4(4):209-16.
View in: PubMed

Top